Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...
In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments ...
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...
Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback